ArticleCancer management and research2025
Clinical Value of Serum sTim-3, CEA, CA15-3 for Postoperative Recurrence of Breast Cancer.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sensitivity Enhancement of Multiplex Lateral Flow Immunoassays by NIR-II Fluorescence and Thermal Contrast.Analytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical value of serum soluble T cell immunoglobulin 3 (sTim-3) on postoperative recurrence of breast cancer (BC). Methods: A highly sensitive time-resolved fluorescence immunoassay (TRFIA) was employed to measure sTim-3. Quantification of serum sTim-3 in 172 BC patients more than one-year postoperative (96 patients with stage I + II, 76 patients with stage III + IV; 31 patients with postoperative recurrence, and 141 patients with postoperative non-recurrence) and 51 healthy controls (HC). To evaluate the difference of serum sTim-3 in different stages of BC and its clinical value for postoperative recurrence of BC. Results: The serum sTim-3 level of BC patients with stage III + IV (21.62 (17.27, 29.78)) were significantly higher than HC (4.49 (3.30, 7.60)), patients with stage I + II (14.96 + 4.94) (P < 0.0001). Serum sTim-3 level of BC patients with postoperative recurrence (21.8(12.40,34.20) were significantly higher than those without recurrence (17.13 ± 6.44) (P = 0.0130). When the serum sTim-3 level was below 11.8 ng/mL, the negative predictive values of sTim-3, CEA and CA15-3 were 90.9%, 68.0% and 67.1%, respectively, and the negative likelihood ratios were 0.16, 0.77 and 0.81, respectively. The positive rate of combined detection of sTim-3, CEA and CA15-3 was 58.1%, higher than single detection of CEA (22.6%) and CA15-3 (19.4%). Conclusion: Serum sTim-3 levels may assist in the staging of BC. Combined detection of sTim-3, CEA, and CA15-3 can be used to routinely monitor the progression of BC and indicate the risk of postoperative BC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.